Chlamydia trachomatis is Gram-negative bacterium that caused ~128.5m new infections in 2020 (15-49 yrs) and is responsible
for one of the most common sexually transmitted infections (STI) worldwide. Although mostly asymptomatic, in the female, untreated ascending CT infections
can result in severe sexual reproductive health (SRH) outcomes of pelvic inflammatory disease (PID), ectopic pregnancy, and infertility.
CT infection can also elevate the risk for HIV acquisition/transmission and cause neonatal conjunctivitis which can cause blindness. In the developing world, CT is responsible for trachoma, the leading cause of infectious blindness, worldwide.
Although CT infections are generally treatable with antibiotics, the bacterium has a high rate of re-infection because of silent carriage in younger persons.
A prophylactic chlamydia trachomatis-specific vaccine impacting upon chlamydial infection or disease course could reduce
adverse SRH outcomes and also alleviate antibiotic consumption. The vaccine could be targeted routinely to adolescents/young adults or high-risk groups (GBMSM)
associated with the highest number of diagnoses. It could also have developing world utility for both genital and ocular disease. Notable vaccines in development are CTH522 (Phase 1/2) (Statens Serum Institute),
the multi-antigen mRNA approach (Sanofi Pasteur, Phase 1/2), an saRNA approach (Ziphius, preclinical) and other approaches from Abera, UNC School of Medicine + others.
This MarketVIEW product is a comprehensive Executive Presentation (>225 slides, .pdf) and interactive MS-Excel
forecast model (150 worksheets, .xls) which investigate the scenario-based uptake and commercial potential of Chlamydia trachomatis specific vaccines across key target groups in 18 high-income nations (public/private), BRICM and GAVI (40 countries) worldwide. A thorough review of the latest disease background and epidemiology is presented along with discussion
of latest understanding of vaccinology/R&D competitor landscape. The analysis contains an in-depth commercial assessment
of potential Chlamydia trachomatis specific vaccine profiles [urogenital + ocular] with discussion around target population rationale, potential uptake, pricing, and clinical development feasibility/issues.
THIS PRODUCT IS A SUMMARY PRESENTATION (~225 slides, .pdf) + 1 scenario-based interactive MS Excel Workbook(s)
Photo credit(s): Priscilla Du Preez (@unsplash license)
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.
